We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$664M
Cap. Flow
-$732M
Cap. Flow %
-58.11%
Top 10 Hldgs %
59.75%
Holding
95
New
14
Increased
22
Reduced
15
Closed
35

Top Buys

Rank Stock Value
1
BIOA
BioAge Labs
BIOA
+$46.2M
2
INCY icon
Incyte
INCY
+$45.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$22.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.7M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$13.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$100M
2
SYK icon
Stryker
SYK
+$65.7M
3
ALGN icon
Align Technology
ALGN
+$52.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$38.8M
5
EW icon
Edwards Lifesciences
EW
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$197M 15.62%
1,550,280
– –
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$123M 9.8%
2,793,987
– –
NVO
3
Novo Nordisk
NVO
$216B
$86.5M 6.86%
726,329
+76,788
+12% +$10.2M
AZN icon
4
AstraZeneca
AZN
$263B
$63.1M 5%
404,703
+3,994
+1% +$645K
IDYA icon
5
IDEAYA Biosciences
IDYA
$3.41B
$55.4M 4.4%
1,749,455
+597,927
+52% +$22.7M
ELAN icon
6
Elanco Animal Health
ELAN
$12.4B
$51.7M 4.1%
3,518,684
+654,434
+23% +$9.12M
BIOA
7
BioAge Labs
BIOA
$968M
$47.9M 3.81%
+2,304,901
New +$46.2M
INCY icon
8
Incyte
INCY
$23.5B
$47.2M 3.75%
+714,176
New +$45.5M
RAPP
9
Rapport Therapeutics
RAPP
$1.95B
$40.9M 3.24%
1,995,594
+44,032
+2% +$946K
AVBP icon
10
ArriVent BioPharma
AVBP
$1.48B
$39.9M 3.16%
1,696,752
– –
AXSM icon
11
Axsome Therapeutics
AXSM
$12.4B
$34.1M 2.71%
379,527
+69,329
+22% +$6.05M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$29.6M 2.35%
586,344
+31,985
+6% +$1.53M
YMAB
13
DELISTED
Y-mAbs Therapeutics
YMAB
$28.9M 2.29%
2,194,278
– –
DYN icon
14
Dyne Therapeutics
DYN
$4.04B
$27.7M 2.2%
772,070
-853,633
-53% -$34M
COGT icon
15
Cogent Biosciences
COGT
$6.79B
$24.5M 1.94%
2,265,230
-508,056
-18% -$4.95M
SVRA icon
16
Savara
SVRA
$1.13B
$24M 1.91%
5,662,550
+303,632
+6% +$1.34M
NVS icon
17
PUT
Novartis
NVS
$295B
$23M 1.83%
+200,000
New +$22.7M
INZY
18
DELISTED
Inozyme Pharma
INZY
$22.4M 1.78%
4,280,308
– –
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$15.9B
$21M 1.67%
+188,562
New +$20.7M
INSM icon
20
Insmed
INSM
$23.2B
$20.9M 1.66%
286,307
+58,560
+26% +$4.32M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.84B
$15.1M 1.2%
786,999
-1,366,670
-63% -$28.2M
SLNO
22
PUT
DELISTED
Soleno Therapeutics
SLNO
$15.1M 1.2%
+300,000
New +$14.4M
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$7B
$14.5M 1.15%
+276,678
New +$13.3M
AXSM icon
24
PUT
Axsome Therapeutics
AXSM
$12.4B
$13.5M 1.07%
+150,000
New +$13.1M
EW icon
25
Edwards Lifesciences
EW
$47.6B
$13.4M 1.06%
202,898
-521,327
-72% -$37.9M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2024 Portfolio in Review

As of Q3 2024, Sofinnova Investments held 95 positions worth $1.26B, down 35% from $1.92B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments withdrew a net $732M in Q3 2024, closing 35 positions and reducing 15 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $100M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 82% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in BioAge Labs worth $47.9M.

  • Sofinnova Investments's largest Q3 2024 buy was BioAge Labs: 2,304,901 shares worth $47.9M.
  • Sofinnova Investments added most to IDEAYA Biosciences in Q3 2024, an estimated $22.7M increase.
  • Sofinnova Investments's biggest Q3 2024 reduction was Edwards Lifesciences, cutting an estimated $37.9M.
  • Sofinnova Investments fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $100M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.26B portfolio in Q3 2024.
  • Sofinnova Investments opened 14 new positions and closed 35 in Q3 2024.
  • Sofinnova Investments's portfolio value fell 35% quarter-over-quarter to $1.26B.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.